The 2026 MIPS quality measures CMS lists as relevant to Pathology. Pick the highest-scoring set for your practice — our certified consultants can help.
Reporting MIPS for a Pathology practice means choosing 6 quality measures — including at least one Outcome or other High Priority measure — and reporting each on as many eligible cases as possible to be scored against CMS's national benchmarks. The measures below are the ones CMS lists as relevant to Pathology; open any for its full numerator, denominator, and exclusions.
Percentage of esophageal biopsy reports that document the presence of Barrett’s mucosa that also include a statement about dysplasia. Instructions This measure is to be submitted each time a patient’s esophageal surgical pathology report demonstrates Barrett’s Esophagus; however, only one quality data code (QDC) per…
Percentage of radical prostatectomy pathology reports that include the pT category, the pN category, the Gleason score and a statement about margin status. Instructions This measure is to be submitted each time a radical prostatectomy surgical pathology examination is performed during the performance period for…
Pathology reports based on lung biopsy and/or cytology specimens with a diagnosis of primary non-small cell lung cancer classified into specific histologic type following the International Association for the Study of Lung Cancer (IASLC) guidance or classified as non-small cell lung cancer not otherwise specified…
Pathology reports based on lung resection specimens with a diagnosis of primary lung carcinoma that include the pT category, pN category and for non-small cell lung cancer (NSCLC), histologic type. Instructions This measure is to be submitted each time a patient’s lung pathology report addresses…
Pathology reports for primary malignant cutaneous melanoma that include the pT category, thickness, ulceration and mitotic rate, peripheral and deep margin status and presence or absence of microsatellitosis for invasive tumors. Instructions This measure is to be submitted each time a patient’s pathology report addresses…
Percentage of biopsies with a diagnosis of cutaneous basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), or melanoma (including in situ disease) in which the pathologist communicates results to the clinician within 7 days from the time when the tissue specimen was received by…
Percentage of surgical pathology reports for primary colorectal, endometrial, gastroesophageal or small bowel carcinoma, biopsy or resection, that contain impression or conclusion of or recommendation for testing of mismatch repair (MMR) by immunohistochemistry (biomarkers MLH1, MSH2, MSH6, and PMS2), or microsatellite instability (MSI) by DNA-based…
Our AAPC-certified MIPS experts map the highest-scoring measures to your specialty and manage your reporting end-to-end.
Talk to an expert